^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EMB-02

    i
    Other names: EMB-02, EMB02, EMB 02
    Associations

    News

    Trials
    Company:
    EpimAb Biotherap
    Drug class:
    PD1 inhibitor, LAG-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    A Study of EMB-02 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=47, Terminated, Shanghai EpimAb Biotherapeutics Co., Ltd. | Trial completion date: Dec 2025 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Jul 2023; Company's resource optimization and product's development change
    Trial completion date • Trial termination • Trial primary completion date
    |
    EMB-02
    over1year
    Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors (ESMO 2023)
    Conclusions EMB-02 has demonstrated a tolerable safety profile and encouraging anti-tumor activity during the dose escalation phase, warranting further development. Expansion cohorts in select advanced solid tumours are ongoing.
    Clinical • P1 data • Metastases
    |
    LAG3 (Lymphocyte Activating 3)
    |
    LAG3 expression
    |
    EMB-02